Researchers found substantial overlap in autonomic symptoms, orthostatic tachycardia, and functional impairment between long COVID and POTS.
|Articles|May 2, 2022
Daily OTC Pearl: OTC Migraine Relief
Author(s)Saro Arakelians, PharmD
Nonprescription migraine pain reliever combines acetaminophen, aspirin, and caffeine to relieve migraine pain.
Advertisement
OTC/Lifestyle Pearl of the Day: OTC Migraine Relief
Indication: Nonprescription migraine pain reliever combines acetaminophen, aspirin, and caffeine to relieve migraine pain.
Insight:
- OTC Migraine Relief combines acetaminophen 250 mg, aspirin (nonsteroidal anti-inflammatory drug) 250 mg, and caffeine 65 mg.
- Gluten-free migraine relief approved for adults 18 years of age and over.
- For adults: CVS Health Migraine Relief treats migraine headaches in adults. Use a 2-caplet dose for migraine pain relief. Under 18 years of age, ask a physician.
- This product comes in caplets.
Source:
Advertisement
Related to this article
A review of 69 studies finds influenza vaccines continue to reduce hospitalization and death, with no new safety concerns.
Isatuximab plus Iberdomide maintenance helps MRD-positive myeloma patients turn MRD-negative after transplant, with manageable safety.
Insulin efsitora alfa-gobe (Onswik; Eli Lilly and Company) is designed to deliver steady basal insulin levels over a full 7-day duration.
Vallerie McLaughlin, MD, explains why the ERS update strongly recommends sotatercept for patients with pulmonary arterial hypertension (PAH) who don't reach low-risk status on initial therapy.
Imaging data from the CONTENTed study suggest the type 2 inflammation that drives severe asthma may affect more than the airways.
Renal benefit appeared only in patients with albuminuria in a 75,455-person BMJ analysis, whereas sulfonylureas signaled faster decline without it.
Authors of a pharmacist-directed transitions-of-care study discuss what drives pneumococcal vaccine hesitancy and how pharmacists can build systematic vaccine screening into inpatient workflows.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Nearly Two-Thirds of Patients With Long COVID Meet Diagnostic Criteria for POTS
2
After 180 Years, Multiple Myeloma Gets a Definition of Cure
3
Teclistamab-Daratumumab Intensification Achieves 73% MRD-Negative CR Rate in High-Risk Multiple Myeloma
4
Influenza Vaccines Continue to Reduce Severe Disease and Death Across High-Risk Groups, Evidence Review Finds
5